a Department of Infectious Diseases , the First Affiliated Hospital of Wenzhou Medical University, Hepatology Institute of Wenzhou Medical University, Wenzhou Key Laboratory of Hepatology , Wenzhou , China.
b State Key Laboratory of Infectious Diseases , Medicine School of Zhejiang University , Hangzhou , China.
Expert Rev Gastroenterol Hepatol. 2018 May;12(5):491-502. doi: 10.1080/17474124.2018.1460202. Epub 2018 Apr 2.
A number of researches have explored the association between obesity and nonalcoholic fatty liver disease (NAFLD) liver function, histopathology, complications, genetic factors and prognosis, but the results were conflicting and inconclusive. Areas covered: In this meta-analysis, the liver function, histopathology, metabolic complications, patatin-like phospholipase domain-containing protein 3 (PNPLA3) genetic polymorphism and prognosis were compared between non-obese and obese NAFLD. Pubmed, EMBASE, Cochrane databases were searched to identify eligible studies. The odds ratio (OR) or standardized mean difference (SMD) with 95% confidence intervals (CI) were pooled using fixed- or random-effects models. Expert commentary: This meta-analysis indicated that for NAFLD patients, obesity (according to ethnic-specific BMI cut-off points to define obesity) could predict a worse long-term prognosis. However, obesity may not be an independent factor for the development of NASH or advanced fibrosis in NAFLD patients and NAFLD should be considered as potential population for pharmacologic treatment regardless of obesity. In addition, PNPLA3 rs738409 may be more relevant to the progression of non-obese NAFLD when compared to obese NAFLD. Importantly, large-sample, long-term follow-up cohort studies based on liver biopsy are highly needed due to limited liver pathology and long-term follow-up data at present.
许多研究探讨了肥胖与非酒精性脂肪性肝病(NAFLD)肝功能、组织病理学、并发症、遗传因素和预后之间的关系,但结果存在争议,尚无定论。
在这项荟萃分析中,比较了非肥胖和肥胖的 NAFLD 患者之间的肝功能、组织病理学、代谢并发症、patatin-like phospholipase domain-containing protein 3(PNPLA3)遗传多态性和预后。通过检索 Pubmed、EMBASE、Cochrane 数据库,以确定合格的研究。使用固定或随机效应模型,汇总了比值比(OR)或标准化均数差(SMD)及其 95%置信区间(CI)。
这项荟萃分析表明,对于 NAFLD 患者,肥胖(根据特定种族的 BMI 切点来定义肥胖)可能预示着更差的长期预后。然而,肥胖可能不是 NAFLD 患者发生 NASH 或晚期纤维化的独立因素,并且无论肥胖与否,NAFLD 都应被视为潜在的药物治疗人群。此外,与肥胖的 NAFLD 相比,PNPLA3 rs738409 可能与非肥胖的 NAFLD 的进展更为相关。重要的是,由于目前肝脏病理学和长期随访数据有限,需要进行基于肝活检的大样本、长期随访队列研究。